Invesco Ltd. Has $6.98 Million Stock Position in Xencor, Inc. $XNCR

Key Points

• Invesco Ltd. increased its holdings in Xencor, Inc. by 44.3% during the first quarter, now owning approximately 0.92% of the company, valued at nearly $7 million.
• Several large investors have modified their stakes in Xencor, with US Bancorp DE boosting its holdings by 312.0%, while Barclays set a significantly lower target price of $6.00 with an "underweight" rating.
• Xencor saw a positive earnings report with a decrease in losses, posting earnings of ($0.41) per share, which beat projections, alongside a revenue increase of 82.4% year-over-year.

Invesco Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 44.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 656,201 shares of the biopharmaceutical company's stock after purchasing an additional 201,456 shares during the quarter. Invesco Ltd. owned approximately 0.92% of Xencor worth $6,982,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN increased its position in Xencor by 50.7% during the fourth quarter. Wells Fargo & Company MN now owns 36,086 shares of the biopharmaceutical company's stock worth $829,000 after buying an additional 12,144 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Xencor during the 4th quarter worth about $2,329,000. Dimensional Fund Advisors LP boosted its stake in shares of Xencor by 7.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company's stock worth $34,509,000 after acquiring an additional 102,297 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Xencor by 16.9% during the 4th quarter. MetLife Investment Management LLC now owns 40,740 shares of the biopharmaceutical company's stock valued at $936,000 after acquiring an additional 5,888 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Xencor by 132.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 4,482 shares in the last quarter.

Xencor Price Performance

Shares of Xencor stock traded up $0.08 during midday trading on Monday, hitting $8.13. The company had a trading volume of 769,384 shares, compared to its average volume of 743,533. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $27.24. The business's 50 day simple moving average is $8.28 and its two-hundred day simple moving average is $9.77. The stock has a market cap of $579.83 million, a PE ratio of -3.39 and a beta of 0.82.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm had revenue of $43.61 million during the quarter, compared to the consensus estimate of $22.59 million. During the same period in the prior year, the firm earned ($1.07) EPS. The business's revenue was up 82.4% on a year-over-year basis. On average, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity at Xencor

In related news, Director Ellen Feigal sold 2,993 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. This trade represents a 13.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares in the company, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock worth $103,209 over the last three months. Company insiders own 5.23% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on XNCR shares. Wedbush decreased their target price on Xencor from $31.00 to $26.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Wells Fargo & Company dropped their price target on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Barclays decreased their price objective on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, Royal Bank Of Canada lowered their target price on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, August 21st. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.71.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.